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Abstract: Angiotensin receptor blockers (ARBs) are known to reduce the cardiovascular risk 
in hypertensive patients. This study was designed to examine the effect of an ARB candesartan 
on subclinical atherosclerosis assessed by cardio-ankle vascular index (CAVI) in comparison 
with calcium channel blockers (CCBs) alone in hypertensive patients with metabolic syndrome 
(MetS). A total of 53 consecutive hypertensive patients with MetS were randomly assigned to 
the candesartan group, in which candesartan was added on, or the CCBs group, in which CCBs 
were added on. Clinical and biological parameters were obtained before and after the 12-month 
treatment period. The primary measure of efficacy was the %change in CAVI. When treated 
with candesartan, but not CCBs, CAVI significantly decreased from 8.7 to 7.7 by 11%. Blood 
pressure (BP) significantly decreased with both treatments, but the differences between groups 
were not significant. The changes in other parameters remained unchanged in both the groups. 
Analysis of covariance found that both the BP reduction and the therapy difference contributed 
to the decrease in CAVI, but the BP reduction was not involved in the decrease in CAVI caused 
by the difference in the therapy. Candesartan may be a better antihypertensive drug than CCBs   
to improve subclinical atherosclerosis of patients with MetS.
Keywords: albuminuria, ambulatory blood pressure, calcium channel blockers, carotid 
  intima-media thickness
Introduction
The metabolic syndrome (MetS) describes the presence of a cluster of cardiovascular 
risk factors including visceral obesity, dyslipidemia, hypertension, and glucose intoler-
ance, resulting in a prothrombotic and proinflammatory states.1,2 The presence of the 
MetS predicts a 2- to 4-fold increase in the risk of cardiovascular disease (CVD) and 
death.3,4 Because of its poor prognosis, treatment strategy for subclinical atherosclerosis, 
which subsequently results in clinical events of CVD, is attracting worldwide atten-
tion. In Japan, according to the criteria established by the Japanese Society of Internal 
Medicine, a survey by the ministry of health, labor, and welfare, the prevalence of 
the MetS among males over 40 years of age is 21%, and similar prevalence rate was 
observed in the United States.5
Treatment goal for the MetS is to stop the progression of systemical 
  atherosclerosis. Angiotensin receptor blocker (ARB), irbesartan, is reported to 
reduce cardiovascular risk factors in patients with MetS.6 Candesartan had more 
beneficial effect in reducing CVD than losartan in obese patients. Compared with 
the losartan group, the candesartan group had a lower adjusted hazard ratio for total Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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CVD and peripheral artery disease in hypertensive patients 
with baseline body mass index (BMI) averaging 30.2.7 In 
addition, the subanalysis of Candesartan Antihypertensive 
Survival Evaluation in Japan (CASE-J) study, which com-
pared the effects of candesartan and amlodipine, showed 
that candesartan reduced total mortality, particularly in 
patients with BMI over 27.5 kg/m2. These might suggest 
that candesartan’s beneficial effect on CVD is prominent 
in obese patients. However, there has been no study that 
directly examined the effects of candesartan on the sub-
clinical atherosclerosis or risk of atherosclerotic events in 
patients with MetS.
The aim of this study was to examine the effects of 
  candesartan on arterial stiffness assessed by cardio-ankle 
vascular index (CAVI) and augmentation index (AI) in 
comparison with calcium channel blockers (CCBs) alone 
in hypertensive patients with MetS. CAVI is reported 
to be   associated with the number of the CVD risk fac-
tor   independently of blood pressure (BP) in patients 
with MetS. Recent studies showed that CAVI is less 
BP-dependent marker for arterial stiffness and detects 
arterial stiffness due to fibrosis with higher sensitivity 
and specificity than pulse wave velocity (PWV).8 In addi-
tion, maximum intima-media thickness (max IMT) of the 
carotid artery was evaluated as the parameter of subclini-
cal atherosclerosis, and urinary   albumin excretion (UAE) 
was evaluated as a surrogate marker for cardiovascular 
morbidity and mortality.9
Methods
study population and design
Subjects of this study were 53 consecutive hypertensive 
patients who were previously untreated or treated with 
CCBs (amlodipine, azelnidipine, benidipine, cilnidipine, 
efonidipine, nifedipine, and nisoldipine) in the outpatient 
hypertension clinic of Keio University Medical School 
Hospital. Patients who were treated with angiotensin-
  converting enzyme (ACE) inhibitors or ARBs were 
excluded. All patients fulfilled the diagnostic criteria 
for MetS established by the Japanese Society of Internal 
Medicine. Major criteria: waist size .85 cm for male 
and .90 cm for female; minor   criteria: dyslipidemia (trig-
lycerides [TG] .150 mg/dL and/or high-density lipoprotein 
cholesterol [HDL-C] ,40 mg/dL), hypertension (systolic 
BP . 130 mmHg and/or diastolic BP . 85 mmHg), impaired 
glucose tolerance (fasting blood glucose . 110 mg/dL); pres-
ence of major criteria with 2 or more minor   criterion. Patients 
with a history of diabetes for more than 10 years and patients 
aged 80 years or over were excluded. All hypertensive 
patients were randomly assigned to the candesartan group 
or the CCBs group. In the candesartan group, candesartan 
was added on and the previous treatment was continued. In 
the CCBs group, kind of CCB was unchanged if previously 
prescribed and amlodipine was added if untreated. Cande-
sartan was initially prescribed at a dose of 4 mg/d, and dose 
was subsequently increased to a maximum dose of 16 mg/d 
if the target 24-hour ambulatory BP of ,130/85 mmHg 
was not achieved. In the CCBs group, doses were sub-
sequently increased if the target 24-hour ambulatory BP 
of ,130/85 mmHg was not achieved. 24-hour ambulatory 
BP was monitored every 3 months to assess if the patients 
achieved BP. In the protocol, if the target BP was not 
achieved only by dosing up candesartan or CCBs in each 
group, diuretics or β-blockers or both were planned to 
be added on; however, in this study, all patients achieved 
target 24-hour ambulatory BP without adding diuretics or 
β-blockers. Clinical and biological parameters were obtained 
before and after the 12-month treatment period. This study 
was approved by the review board of Keio University Medi-
cal School Hospital, and informed consent was obtained from 
every subject. The primary measure of efficacy in this study 
was the %change in CAVI, AI, UAE, and carotid IMT.
Brain natriuretic peptide (BNP), potassium (K), creatinine 
(Cr), uric acid (UA), low-density lipoprotein cholesterol 
(LDL-C), HDL-C, TG, and glycated albumin (GA) were 
measured in venous blood samples drawn in the morning 
after an overnight fast on the same day as the CAVI and AI 
measurements.
Ambulatory BP monitoring
The 24-hour ambulatory BP monitoring was performed with 
an oscillometric-based device (TM-2431; A&D Corporation, 
Tokyo, Japan) as described previously.1 Briefly, BP was mea-
sured every 30 minutes during the day (between 6:00 am and 
10:00 pm) and every 60 minutes during the night (between 
10:00 pm and 6:00 am). Mean values and standard deviations 
(SDs) of ambulatory BP for each subject were calculated for 
24 hours. The SD of the ambulatory BP values was recorded 
as the variability of ambulatory BP in this study. The noc-
turnal decrease in BP was calculated as the average systolic 
BP during the day minus the average systolic BP during the 
night. The morning BP surge was calculated as the highest 
systolic BP during the first 2 hours after awaking minus the 
lowest systolic BP during the night.Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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cAVi and Ai
CAVI was measured using a VaSera VS-1000 (Fukuda 
  Denshi, Tokyo, Japan) as described previously.8 Briefly, cuffs 
were applied to the 4 extremities, and   electrocardiographic 
electrodes were attached to the upper extremities. A 
  microphone was placed at the sternal angle to obtain a 
  phonocardiogram. Patients rested in the supine position for 
at least 10 minutes before the start of monitoring.
AI was measured using an automated tonometric 
device (HEM-9000AI; Omron Healthcare, Kyoto, Japan) 
as described previously.8 Briefly, peripheral pressure 
waveforms were recorded over 30 seconds from the radial 
artery at the wrist with the subjects in a sitting position after 
at least 5 minutes rest.
carotid iMT
Ultrasonography B-mode imaging of the carotid artery was 
performed with a PowerVision 6000 machine (Toshiba, Tokyo, 
Japan) at a transducer frequency of 7.5 MHz. Each subject was 
examined in the supine position. Up to 4 cm of the common 
carotid artery and the carotid bulb were scanned bilaterally in 
the longitudinal and the transverse projections. The images 
were focused on the far wall of the artery. IMT was defined 
as the distance between the leading edge of the lumen-intima 
interface and the far wall, and the greatest IMT value in the 
bilateral longitudinal projections was recorded as the max IMT. 
All measurements were performed under blind conditions. The 
mean intraobserver and interobserver coefficients of variation 
for max IMT were 4.3% and 4.7%, respectively.
UAe
UAE was evaluated on the basis of the albumin-to-Cr ratio in 
overnight urine samples. Urinary albumin and Cr concentra-
tions were determined by turbidimetric immunoassay with a 
Superior-Microalbumin kit (DPC Corporation, Tokyo, Japan) 
and by the Jaffé reaction with an autoanalyzer.
statistical analyses
All statistical analyses were performed with StatView 5.0. 
software (SAS Institute Inc, Cary, NC, USA). Student t test 
was used to analyze patients’ baseline characteristics, except 
sex, presence of diabetes, prescription of diuretics and statins, 
which were analyzed by the χ2 test for independence. The 
changes in biological parameters were analyzed by the 2-way 
analysis of variance for repeated measures combined with the 
Dunnett and Tukey-Kramer post hoc tests. The contribution 
of changes in BP to %change in CAVI was tested by analysis 
of covariance. A P , 0.05 was considered significant. Data 
are reported as means ± SD.
Results
Patient characteristics
Table 1 shows mean age, gender distribution, complication of 
diabetes, number of patients taking diuretics and statins, waist 
circumference, CAVI, plasma BNP, UAE, max IMT of the 
carotid arteries, AI, estimated glomerular filtration rate (eGFR), 
serum K, Cr, UA, LDL-C, HDL-C, TG, and GA of the cande-
sartan group and the CCBs group at baseline. Overall mean 
values of waist circumference and BP of the subjects were 
91 ± 8 cm and 152 ± 22/95 ± 12 mmHg, respectively. There 
were no significant differences in baseline variables between 
Table 1 Patient characteristics at baseline
Candesartan CCBs P value
n 27 26
Age, y 52 ± 13 56 ± 8 0.1580
Male, n 23 16 0.0509
Diabetes, n 6 3 0.2987
Prescription of diuretics,  
n
4 1 0.2075
Prescription of statins,  
n
3 5 0.2660
Waist, cm 91.3 ± 7.9 90.9 ± 7.9 0.8945
cAVi 8.7 ± 1.1 9.1 ± 0.7 0.4175
Plasma BnP, mg/dL 18.0 ± 16.2 13.5 ± 12.2 0.6294
UAe, log, (mg/gcr) 1.14 ± 0.32 1.53 ± 0.35 0.2007
Max iMT, mm 0.90 ± 0.32 1.20 ± 0.00 0.1322
Ai, % 80.1 ± 12.2 80.8 ± 14.2 0.9001
egFR, mL/min/1.73 m 68.4 ± 21.7 67.5 ± 18.4 0.8947
serum potassium,  
meq/L
4.2 ± 0.4 4.1 ± 0.3 0.5683
serum creatinine,  
mg/dL
1.0 ± 0.6 0.8 ± 0.3 0.3643
serum uric acid,  
mg/dL
6.3 ± 1.2 5.6 ± 1.3 0.1405
serum LDL-c,  
mg/dL
117 ± 33 135 ± 39 0.1914
serum HDL-c,  
mg/dL
48 ± 14 55 ± 16 0.3206
serum triglycerides,  
mg/dL
194 ± 168 130 ± 64 0.0811
serum glycated albumin,  
g/dL
14.5 ± 1.8 13.2 ± 1.1 0.2575
Plasma active renin  
concentration, pg/mL
8.5 ± 6.8 11.8 ± 15.3 0.4177
Note: Data are mean ± sD.
Abbreviations: ccBs, calcium channel blockers; cAVi, cardio-ankle vascular index; 
BnP, brain natriuretic peptide; UAe, urine albumin excretion; Max iMT, maximum 
intima-media  thickness  of  the  carotid  arteries;  Ai,  augmentation  index;  egFR, 
estimated glomerular filtration rate; HDL-C, high-density lipoprotein cholesterol; 
LDL-c, low-density lipoprotein cholesterol; sD, standard deviation.Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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the 2 groups. The average dose of candesartan prescribed at 
the end of the observation period was 13.8 ± 4.7 mg/d.
clinic and ambulatory BP
Table 2 shows the clinic BP and 24-hour ambulatory BP in 
the candesartan group and the CCBs group at baseline and 
after 12-month observation period. The baseline values of the 
clinic systolic/diastolic BP and 24-hour ambulatory systolic/
diastolic BP were similar in the candesartan group and in the 
CCBs group. The clinic systolic/diastolic BP and 24-hour 
ambulatory diastolic BP significantly decreased in both the 
groups. However, 24-hour ambulatory systolic BP and BP 
variability assessed on the basis of the SD of 24-hour systolic 
BP remained unchanged in both the groups. The nocturnal 
BP decrease and morning BP surge were similar in both the 
groups, and they had not changed significantly during the 
12-month treatment period in either group.
Target-organ damage
Figure 1A shows that CAVI decreased significantly, from 
8.7% ± 1.1% to 7.7% ± 0.8% by −11% ± 10%, in the 
  candesartan group, but remained unchanged in the CCBs group 
(9.1% ± 0.7% to 8.9% ± 0.9% by 2% ± 8%). Figure 1B shows 
%change in CAVI during the 12-month treatment period with 
candesartan or CCBs, and the values differed significantly 
among the 2 groups. Figure 2 shows plasma BNP, UAE, max 
IMT, and AI values at baseline and 12 months after the treat-
ment with candesartan or CCBs. They remained unchanged 
during the 12-month treatment period and were similar in both 
the groups.
Factors affecting cAVi
In the candesartan group, CAVI and BP (clinic systolic/
diastolic and 24-hour ambulatory diastolic) values 
significantly decreased during the 12-month treatment 
period. Table 3 shows that the decreases in both 24-hour 
  ambulatory systolic/diastolic BP significantly contributed 
to the %decrease in CAVI during the treatment period. 
However, no interactive effect between the treatments and 
the decreases in 24-hour ambulatory BP was observed, sug-
gesting that the decrease in 24-hour ambulatory BP caused 
by candesartan did not contribute to the decrease in CAVI 
of the hypertensive patients. The changes in clinic systolic/
diastolic BP, variability of 24-hour BP, nocturnal decrease 
or morning surge values did not contribute to the decrease 
in CAVI during the 12-month treatment period.
Parameters of renal function  
and metabolism
Figure 3 shows eGFR, serum K, Cr, and UA values at 
  baseline and 12 months after the treatment with candesartan 
or CCBs. They remained unchanged during the 12-month 
treatment period and were similar in both the groups.
Figure 4 shows LDL-C, HDL-C, TG, and GA values at 
baseline and 12 months after the treatment with candesartan 
and CCBs. They remained unchanged during the 12-month 
treatment period and were similar in both the groups.
Discussion
When treated with candesartan, CAVI significantly decreased 
in patients with MetS. At the same time, 24-hour ambulatory 
BP significantly decreased, both in the candesartan group and in 
the CCBs group. In the candesartan group, systolic and diastolic 
BPs decreased by 36 mmHg and 24 mmHg, respectively, and 
in the CCBs group, systolic and diastolic BPs decreased by 
11 mmHg and 9 mmHg, respectively. Although BP seemed to 
decrease more in the candesartan group, there was no statistical 
significant difference between both the groups. The decrease 
Table 2 clinic and ambulatory BP before and after treatments
Candesartan (n = 26) CCBs (n = 27) Intergroup 
P value Baseline 12 mo Baseline 12 mo
clinic
  systolic BP 157 ± 23 136 ± 13* 156 ± 21 143 ± 9* 0.7033
  Diastolic BP 99 ± 12 87 ± 9* 95 ± 11 87 ± 8* 0.5969
24-h ambulatory BP
  systolic BP 143 ± 15 120 ± 15 140 ± 11 124 ± 12 0.3509
  Diastolic BP 92 ± 10 76 ± 7* 88 ± 5 77 ± 4* 0.2478
  Variability 20 ± 11 16 ± 3 20 ± 5 19 ± 5 0.7718
  nocturnal decrease 16 ± 7 10 ± 13 17 ± 11 18 ± 13 0.5592
  Morning surge 47 ± 23 32 ± 11 46 ± 16 33 ± 17 1.0000
Note: Data are mean ± sD. *P , 0.05 vs baseline. 
Abbreviations: BP, blood pressure; ccBs, calcium channel blockers; sD, standard deviation.Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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in 24-hour ambulatory BP   contributed to the %decrease in 
CAVI. Analysis of covariance was   performed to examine if 
the decrease in 24-hour ambulatory BP is the only factor 
contributed to the %decrease in CAVI in the candesartan 
group. As a result, the difference in the treatment also con-
tributed to the %decrease in CAVI, and no interactive effect 
of the decrease in 24-hour ambulatory BP on the decrease 
in CAVI due to the difference in the treatment was observed. 
This suggests that candesartan may decrease CAVI at least 
in part through its BP-independent effects, although the 
decrease in BP was one of the contributors to the decrease 
in CAVI. The suppression of the renin–  angiotensin system 
by candesartan and/or its own pharmacological effects may 
  contribute to the decrease in CAVI. Angiotensin II accelerates 
the development of atherosclerosis by activating angiotensin 
II type 1 receptors (AT1Rs) that then promote superoxide 
anion generation and oxidative stress, leading to activation 
of nuclear transcription factor and endothelial dysfunction.10 
Mechanical stretching has been cited as the cause of cardiac 
hypertrophy, and investigation into this process with ARBs 
has indicated that AT1Rs are involved in stretch-induced 
hypertrophic responses. Mechanical stretching stimulates 
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Table 3 effects of candesartan and %change in BP on %change in cAVi
Analysis of covariance Coefficient Standard error t-test P value
clinic systolic BP
  group (candesartan vs ccBs) −2.373 2.896 −0.819 0.4246
  %change in systolic BP 0.358 0.229 1.562 0.1379
  group × %change in systolic BP 0.116 0.229 0.507 0.6192
clinic diastolic BP
  group (candesartan vs ccBs) −1.120 3.528 −0.317 0.7551
  %change in diastolic BP 0.148 0.346 0.427 0.6748
  group × %change in diastolic BP 0.332 0.346 0.959 0.3517
24-h ambulatory systolic BP
  group (candesartan vs ccBs) −14.855 1.998 −7.433 0.0176
  %change in systolic BP −1.237 0.141 −8.751 0.0128
  group × %change in 24-h systolic BP 0.264 0.141 1.866 0.2031
24-h ambulatory diastolic BP
  group (candesartan vs ccBs) −19.870 3.728 −5.330 0.0334
  %change in diastolic BP −1.825 0.245 −7.453 0.0175
  group × %change in 24-h diastolic BP 0.258 0.245 1.055 0.4019
BP variability
  group (candesartan vs ccBs) −7.478 2.413 −3.099 0.0903
  %change in variability of BP −0.013 0.099 −0.128 0.9100
  group × %change in variability of BP 0.365 0.099 3.691 0.0662
nocturnal decrease
  group (candesartan vs ccBs) −7.048 6.557 −1.075 0.3949
  %change in nocturnal decrease 0.036 0.78 0.464 0.6885
  group × %change in nocturnal decrease 0.036 0.078 0.020 0.9861
Morning surge
  group (candesartan vs ccBs) −8.894 4.558 −1.951 0.1903
  %change in morning surge −0.083 0.088 −0.948 0.4432
  group × %change in morning surge 0.064 0.088 0.724 0.5441
Abbreviations: BP, blood pressure; cAVi, cardio-ankle vascular index; ccBs, calcium channel blockers.
AT1Rs independently of angiotensin II, and candesartan 
was reported to inhibit this stimuli as an inverse agonist.11 
This mechanism may also work present in the arterial 
smooth muscle, and candesartan might have suppressed 
the hypertrophic change of the arterial walls resulting 
in the decrease in CAVI. In addition, a previous study 
demonstrated that a long-term treatment with candesartan 
increases the expression of peroxisome proliferator-acti-
vated receptor-γ (PPAR-γ) messenger RNA in rats.12 Since 
stimulation of PPAR-γ resulted in the decrease in PWV13 
through up-regulating adiponectin and down-regulating 
inflammatory markers in the plasma,14 antiatherosclerotic 
effects of PPARγ might be also involved in the reduction 
of CAVI by the candesartan treatment.
Studies showed that the 24-month treatment with cande-
sartan reduced AI15 and decreased carotid IMT by enhancing 
nitric oxide and decreasing oxidative stress in hypertensive 
patients,16 although 12-month treatment with candesartan was 
reported not to decrease carotid max IMT.17 In this study, AI 
or carotid max IMT remained unchanged during 12-month 
treatment with candesartan. More extended treatment period 
with candesartan might be required to obtain the significant 
improvement of AI and carotid IMT.
Metabolic parameters, such as serum levels of LDL-C, 
HDL-C, TG, and GA, remained unchanged in this study, 
as well as in a recent study which showed that candesartan 
had no effect on serum lipoprotein levels in hyperten-
sive patients.10 In the CASE-J study, however, new-onset 
diabetes occurred fewer in patients taking candesartan 
than in those taking amlodipine resulting in a 36% relative 
risk reduction, suggesting beneficial effect of candesartan 
on glucose tolerance.20 The patients in the CASE-J study 
were treated for 3.2 years, whereas patients in this study 
were treated for only 1 year. To obtain beneficial effect of 
candesartan on glucose tolerance, longer treatment period 
may be required.
Among ARBs, candesartan is known to have more 
  beneficial effect in reducing CVD, in patients whose BMI 
was 30.2.7 The subanalysis of CASE-J study, which   compared 
the effects of candesartan and amlodipine, showed that 
  candesartan reduces total mortality, particularly in patients 
with BMI over 27.5 kg/m2.Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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One of the limitations in this study was that hard 
  outcomes were not examined. Also, the trial population 
was   comparatively small in number and the treatment 
period was comparatively short. Although there were no 
significant differences in baseline characteristics between 
both groups, candesartan group tended to be younger, more 
frequently male and diabetic. Since different types of CCBs 
were   prescribed in the CCBs group, we have to note that this Vascular Health and Risk Management
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study cannot deny the effectiveness of a specific CCB. These 
are the limitations of this study, and further studies will be 
needed to confirm the efficacy of candesartan.
In conclusion, candesartan significantly decreased CAVI 
in hypertensive patients with MetS, but CCBs did not, 
although both antihypertensive drugs similarly decreased 
BPs. Candesartan may be an useful antihypertensive 
drug to improve subclinical atherosclerosis developed in 
  hypertensive patients with MetS.
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